Esperion Therapeutics, Inc. (0IIM.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
3891 Ranchero Drive
Ann Arbor, MI 48108
United States of America (the)
Phone
734 887 3903
Website
Sector
Healthcare
Industry
Biotechnology
Employees
304
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Sheldon L. Koenig | President, Chief Executive Officer & Director | 1.43M | 1966 |
| John Harlow | Chief Commercial Officer | 582,940 | 1976 |
| Benjamin O. Looker | Chief Legal and Corporate Affairs Officer | 696,350 | 1982 |
| Benjamin Halladay | Chief Financial Officer | 755,083 | 1986 |
| Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development | 0 | N/A |
| Betty Jean Swartz | Chief Business Officer | 0 | N/A |
| Tiffany Aldrich | Associate Director of Corporate Communications | 0 | N/A |
| LeAnne Bloedon | Vice President & Head of Development | 0 | N/A |
| Glenn Brame | Chief Technical Operations Officer | 0 | 1957 |
Esperion Therapeutics, Inc. operates as a pharmaceutical company primarily focused on developing and commercializing medications designed to manage elevated low-density lipoprotein (LDL) cholesterol levels in patients. Its flagship pharmaceutical products include NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe) in tablet form. These treatments are prescribed for individuals suffering from atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). Additionally, Esperion has established strategic licensing and collaborative partnerships with Daiichi Sankyo Europe GmbH and Serometrix to obtain rights to an oral, small molecule PCSK9 inhibitor program. The company was founded in 2008 and its principal offices are located in Ann Arbor, Michigan.